| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.64 [0.49, 0.84] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | crucial | - |
| progression or deaths (PFS) | 0.56 [0.45, 0.70] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| objective responses (ORR) | 2.20 [1.57, 3.09] | | > 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| AE (any grade) | 1.20 [0.36, 3.96] | | < 1 | | 0% | 1 study (1/-) | 38.5 % | NA | not evaluable | | non important | - |
| AE (grade 3-4) | 0.99 [0.70, 1.39] | | < 1 | | 0% | 1 study (1/-) | 52.7 % | NA | not evaluable | | non important | - |
| AE leading to death (grade 5) | 1.31 [0.69, 2.49] | | < 1 | | 0% | 1 study (1/-) | 20.3 % | NA | not evaluable | | non important | - |
| AE leading to treatment discontinuation (any grade) | 2.28 [1.45, 3.61] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| AE leading to treatment discontinuation (grade 3-4) | 2.09 [1.28, 3.39] | | < 1 | | 0% | 1 study (1/-) | 0.2 % | NA | not evaluable | | non important | - |
| TRAE leading to death (grade 5) | 1.70 [0.61, 4.75] | | < 1 | | 0% | 1 study (1/-) | 15.5 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
| hepatitis (Autoimmune) AE (grade 3-4) | 10.24 [0.56, 188.30] | | < 1 | | 0% | 1 study (1/-) | 6.1 % | NA | not evaluable | | non important | - |
| Alopecia AE (grade 3-4) | 0.33 [0.03, 3.22] | | < 1 | | 0% | 1 study (1/-) | 82.7 % | NA | not evaluable | | non important | - |
| Anaemia AE (grade 3-4) | 0.72 [0.46, 1.11] | | < 1 | | 0% | 1 study (1/-) | 93.3 % | NA | not evaluable | | non important | - |
| Arthralgia AE (grade 3-4) | 2.03 [0.37, 11.17] | | < 1 | | 0% | 1 study (1/-) | 20.9 % | NA | not evaluable | | non important | - |
| Asthenia AE (grade 3-4) | 0.60 [0.21, 1.66] | | < 1 | | 0% | 1 study (1/-) | 83.9 % | NA | not evaluable | | non important | - |
| Colitis AE (grade 3-4) | 2.04 [0.50, 8.23] | | < 1 | | 0% | 1 study (1/-) | 16.0 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 0.67 [0.11, 4.04] | | < 1 | | 0% | 1 study (1/-) | 66.9 % | NA | not evaluable | | non important | - |
| Cough AE (grade 3-4) | 0.67 [0.11, 4.04] | | < 1 | | 0% | 1 study (1/-) | 66.9 % | NA | not evaluable | | non important | - |
| Decreased appetite AE (grade 3-4) | 1.21 [0.37, 4.02] | | < 1 | | 0% | 1 study (1/-) | 37.6 % | NA | not evaluable | | non important | - |
| Diarrhoea AE (grade 3-4) | 1.88 [0.69, 5.16] | | < 1 | | 0% | 1 study (1/-) | 11.0 % | NA | not evaluable | | non important | - |
| Dyspnoea AE (grade 3-4) | 3.04 [0.31, 29.44] | | < 1 | | 0% | 1 study (1/-) | 17.0 % | NA | not evaluable | | non important | - |
| Epistaxis AE (grade 3-4) | 1.01 [0.02, 50.94] | | < 1 | | 0% | 1 study (1/-) | 49.9 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 0.82 [0.33, 2.01] | | < 1 | | 0% | 1 study (1/-) | 66.9 % | NA | not evaluable | | non important | - |
| Hyperthyroidism AE (grade 3-4) | 2.02 [0.07, 60.40] | | < 1 | | 0% | 1 study (1/-) | 34.5 % | NA | not evaluable | | non important | - |
| Hypophysitis AE (grade 3-4) | 4.05 [0.18, 90.23] | | < 1 | | 0% | 1 study (1/-) | 19.1 % | NA | not evaluable | | non important | - |
| Hypothyroidism AE (grade 3-4) | 2.02 [0.07, 60.40] | | < 1 | | 0% | 1 study (1/-) | 34.5 % | NA | not evaluable | | non important | - |
| Infusion-related reaction AE (grade 3-4) | 4.07 [0.45, 36.67] | | < 1 | | 0% | 1 study (1/-) | 10.7 % | NA | not evaluable | | non important | - |
| Myalgia AE (grade 3-4) | 2.02 [0.18, 22.43] | | < 1 | | 0% | 1 study (1/-) | 28.5 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 0.75 [0.17, 3.39] | | < 1 | | 0% | 1 study (1/-) | 64.4 % | NA | not evaluable | | non important | - |
| Neutropenia AE (grade 3-4) | 0.90 [0.61, 1.32] | | < 1 | | 0% | 1 study (1/-) | 70.9 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy AE (grade 3-4) | 1.52 [0.25, 9.15] | | < 1 | | 0% | 1 study (1/-) | 32.6 % | NA | not evaluable | | non important | - |
| Pneumonitis AE (grade 3-4) | 3.07 [0.61, 15.32] | | < 1 | | 0% | 1 study (1/-) | 8.7 % | NA | not evaluable | | non important | - |
| Pyrexia AE (grade 3-4) | 1.01 [0.14, 7.20] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
| Severe skin reactions AE (grade 3-4) | 3.04 [0.31, 29.44] | | < 1 | | 0% | 1 study (1/-) | 17.0 % | NA | not evaluable | | non important | - |
| Thrombocytopenia AE (grade 3-4) | 1.07 [0.55, 2.08] | | < 1 | | 0% | 1 study (1/-) | 42.4 % | NA | not evaluable | | non important | - |
| Thyroiditis AE (grade 3-4) | 2.02 [0.07, 60.40] | | < 1 | | 0% | 1 study (1/-) | 34.5 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 0.16 [0.02, 1.38] | | < 1 | | 0% | 1 study (1/-) | 95.1 % | NA | not evaluable | | non important | - |
